Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.51 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | P4HB | P07237 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28144725 | 0.87 | NOTUM (0.67) | NOTUMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL364772 | 0.85 | RAF1 (0.53) | NOTUMALDH1A1KDRLMNAGAA | |
| SCHEMBL1997248 | 0.84 | NOTUM (0.73) | NOTUMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL16320297 | 0.84 | ESRRA (0.52) | NOTUMKDRPDK1PDK2PDK3 | |
| SCHEMBL10907300 | 0.83 | NOTUM (0.66) | NOTUMALDH1A1PDK1PDK2PDK3 | |
| SCHEMBL403261 | 0.83 | CA12 (0.51) | ALDH1A1KDRLMNAMAPTNPFFR2 | |
| SCHEMBL16319599 | 0.82 | SCN9A (0.52) | NOTUMKDRLMNAGAAMAPT | |
| SCHEMBL21776928 | 0.81 | KDR (0.48) | NOTUMKDRPDK1LMNAGAA | |
| SCHEMBL10861732 | 0.81 | NOTUM (0.64) | NOTUMALDH1A1PDK2LMNAGAA | |
| SCHEMBL14012580 | 0.81 | NOTUM (0.64) | NOTUMALDH1A1PDK2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2023-08-17 | — | — | US | disclosed |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-4148045-A1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3- (TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B] INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-3378854-B1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20220259627-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11149292-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| CN-108558740-B | S1P1 receptor modulators and salts thereof | 艾尼纳制药公司 | 2021-10-19 | — | — | CN | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010028981-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
| WO-2010027431-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010011316-A1 | SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| CN-1087285-C | Basic group substituted benzoyl guanidine, its preparing process, its use as medicine or diagnostic reagent, and medicine containing the same | HOECHST AG (DE) | 2002-07-10 | — | — | CN | disclosed |
| US-6057322-A | USEFUL IN TREATMENT OF CARDIOVASCULAR DISEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | CYP3A7, ECI1, CYP2B6 | NOTUM 782/4885ALDH1A1 39/4885KDR 3511/4885 |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | NOTUM 4619/4885ALDH1A1 708/4885KDR 1165/4885 |
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | NOTUM 1/4885ALDH1A1 1260/4885KDR 4445/4885 |
| US-11674163-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | S1PR1, S1PR5, S1PR2 | NOTUM 3920/4885ALDH1A1 312/4885KDR 92/4885 |
| US-20220259627-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | NOTUM 3903/4885ALDH1A1 302/4885KDR 122/4885 |
| US-20230257349-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | NOTUM 3382/4885ALDH1A1 260/4885KDR 1702/4885 |
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | NOTUM 3382/4885ALDH1A1 260/4885KDR 1702/4885 |
| US-11149292-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | S1PR1, S1PR5, S1PR2 | NOTUM 3920/4885ALDH1A1 312/4885KDR 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.